Teva Pharmaceutical Industries Cost of Goods Sold 2010-2024 | TEVA

Teva Pharmaceutical Industries annual/quarterly cost of goods sold history and growth rate from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
  • Teva Pharmaceutical Industries cost of goods sold for the quarter ending September 30, 2024 was $2.183B, a 9.2% increase year-over-year.
  • Teva Pharmaceutical Industries cost of goods sold for the twelve months ending September 30, 2024 was $8.411B, a 1.67% increase year-over-year.
  • Teva Pharmaceutical Industries annual cost of goods sold for 2023 was $8.2B, a 3.12% increase from 2022.
  • Teva Pharmaceutical Industries annual cost of goods sold for 2022 was $7.952B, a 4.01% decline from 2021.
  • Teva Pharmaceutical Industries annual cost of goods sold for 2021 was $8.284B, a 7.27% decline from 2020.
Teva Pharmaceutical Industries Annual Cost of Goods Sold
(Millions of US $)
2023 $8,200
2022 $7,952
2021 $8,284
2020 $8,933
2019 $9,351
2018 $9,975
2017 $11,770
2016 $10,044
2015 $8,296
2014 $9,216
2013 $9,607
2012 $9,665
2011 $8,797
2010 $7,056
2009 $6,532
Teva Pharmaceutical Industries Quarterly Cost of Goods Sold
(Millions of US $)
2024-09-30 $2,183
2024-06-30 $2,140
2024-03-31 $2,048
2023-12-31 $2,040
2023-09-30 $1,999
2023-06-30 $2,082
2023-03-31 $2,079
2022-12-31 $2,113
2022-09-30 $1,926
2022-06-30 $1,992
2022-03-31 $1,921
2021-12-31 $2,050
2021-09-30 $2,093
2021-06-30 $2,037
2021-03-31 $2,104
2020-12-31 $2,406
2020-09-30 $2,126
2020-06-30 $2,107
2020-03-31 $2,294
2019-12-31 $2,510
2019-09-30 $2,264
2019-06-30 $2,284
2019-03-31 $2,293
2018-12-31 $2,005
2018-09-30 $2,552
2018-06-30 $2,668
2018-03-31 $2,750
2017-12-31 $3,127
2017-09-30 $2,967
2017-06-30 $2,865
2017-03-31 $2,811
2016-12-31 $3,102
2016-09-30 $2,762
2016-06-30 $2,161
2016-03-31 $2,019
2015-12-31 $2,034
2015-09-30 $2,052
2015-06-30 $2,064
2015-03-31 $2,146
2014-12-31 $2,279
2014-09-30 $2,249
2014-06-30 $2,384
2014-03-31 $2,304
2013-12-31 $2,536
2013-09-30 $2,429
2013-06-30 $2,331
2013-03-31 $2,311
2012-12-31 $2,464
2012-09-30 $2,371
2012-06-30 $2,337
2012-03-31 $2,493
2011-12-31 $2,795
2011-09-30 $2,098
2011-06-30 $2,012
2011-03-31 $1,892
2010-12-31 $1,954
2010-09-30 $1,783
2010-06-30 $1,679
2010-03-31 $1,640
2009-12-31 $1,703
2009-09-30 $1,622
2009-06-30 $1,631
2009-03-31 $1,576
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.395B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00